Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia (NCT00070499)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Patients must have CML in chronic phase based on bone marrow aspiration and biopsy and peripheral blood counts obtained within 28 days before registration
2. Patients must be registered on this study within 180 days after the date of first being diagnosed with CML, based on a cytogenetic or molecular analysis of peripheral blood or bone marrow, demonstrating the presence of the Philadelphia chromosome or variants of the (9;22) translocation or testing positive for Bcr-Abl by real time-polymerase chain reaction (RT-PCR); patients may have secondary chromosomal abnormalities in addition to the Philadelphia chromosome and remain eligible
3. Patients must have Zubrod performance status 0-2
4. Patients must not have received prior treatment for CML with the exception of hydroxyurea and/or anagrelide
5. Patients must not have received any prior chemotherapy regimen for peripheral blood stem cell mobilization; (prior collection of unmobilized peripheral blood stem cells is permitted)
6. Serum bilirubin =\< 2.0 x the institutional upper limit of the normal (IULN)
7. Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) or serum glutamate pyruvate transaminase (SGPT)/alanine transaminase (ALT) =\< 2.0 x the IULN
8. Patients (Southwestern Oncology Group \[SWOG\] institutions only) must be registered on SWOG-9007, "Cytogenetic Studies in Leukemia Patients;" collection of the pretreatment bone marrow specimen must be completed within 28 days prior to registration; the pretreatment bone marrow specimen must be submitted to an approved Southwest Oncology Group Cytogenetics Laboratory for cytogenetic analysis as described, and an aliquot of the bone marrow (or peripheral blood if the marrow aspiration is a dry tap) must be submitted for fluorescent in situ hybridization (FISH) analysis; note that protocol SWOG-9007 also requires submission of bone marrow specimens at the time of progression to the accelerated or blastic phase of CML or the loss of complete hematologic response and every six months while the patient is on this study
9. Patients (SWOG institutions only) must be registered on S9910, "Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary;" specimens of peripheral blood and bone marrow must be submitted to the Southwest Oncology Group Lymphoid Leukemia and CML Centralized Laboratory in Seattle, Washington; collection of pretreatment blood and marrow specimens must be completed within 28 days prior to registration; note that this study also requires submission of peripheral blood and bone marrow specimens at various times after entry into the study
10. Patients must not have undergone major surgery within 28 days before registration, and must have fully recovered from any other prior major surgery
11. Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method
12. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, cervical carcinoma in situ, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for five years

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (340 Sites)

• Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
• City of Hope Comprehensive Cancer Center — Duarte, California
• Kaiser Permanente-Fremont — Fremont, California
• USC / Norris Comprehensive Cancer Center — Los Angeles, California
• Kaiser Permanente-Oakland — Oakland, California
• Kaiser Permanente-Redwood City — Redwood City, California
• Kaiser Permanente-Richmond — Richmond, California
• Kaiser Permanente-Roseville — Roseville, California
• Kaiser Permanente-South Sacramento — Sacramento, California
• Kaiser Permanente Sacramento Medical Center — Sacramento, California
• Kaiser Permanente-San Francisco — San Francisco, California
• Kaiser Permanente-Santa Teresa-San Jose — San Jose, California
• Kaiser Permanente San Leandro — San Leandro, California
• Kaiser Permanente-San Rafael — San Rafael, California
• Kaiser Permanente Medical Center - Santa Clara — Santa Clara, California
• Kaiser Permanente-Santa Rosa — Santa Rosa, California
• Kaiser Permanente-South San Francisco — South San Francisco, California
• Kaiser Permanente-Stockton — Stockton, California
• Kaiser Permanente-Vallejo — Vallejo, California
• Kaiser Permanente-Walnut Creek — Walnut Creek, California
• Rocky Mountain Regional VA Medical Center — Aurora, Colorado
• UCHealth University of Colorado Hospital — Aurora, Colorado
• Poudre Valley Hospital — Fort Collins, Colorado
• Montrose Memorial Hospital — Montrose, Colorado
• Intermountain Health Lutheran Hospital — Wheat Ridge, Colorado

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.